Imiquimod

Current Opinion in Infectious Diseases

Volumn 16, Issue 2, 2003, Pages 85-89

  Garland, Suzanne M ^a  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

Author keywords

Basal cell carcinomas; Genital warts; Imiquimod; Immunostimulator; Topical immunomodifer

Indexed keywords

CYTOKINE; IMIQUIMOD; RESIQUIMOD;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; BASAL CELL CARCINOMA; BOWEN DISEASE; BOWENOID PAPULOSIS; CONDYLOMA; CONDYLOMA ACUMINATUM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EROSION; ERYTHEMA; FEMALE; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOREGULATION; IMMUNOSTIMULATION; MALE; MOLLUSCUM CONTAGIOSUM; POXVIRUS; REVIEW; SKIN EDEMA; TH1 CELL; WART VIRUS;

EID: 0037398221     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200304000-00004     Document Type: Review

References (53)

1. Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators: progress towards treating inflammation, infection and cancer. Lancet Infect Dis 2001; 1:189-198. This is a good review of the mechanism of action and clinical trial data for imiquimod and resiquimod.
2. Marini M. Imiquimod 5% cream: a topical immune response modifier. Int J Dermatol 2002; 41 (Suppl 1):1-2.
3. Miller R. Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. Int J Dertmatol 2002; 41 (Suppl 1):3-6. This is a review of imiquimod's mechanism of action and role in HPV related disease.
4. Dockrell DH, Kinghorn GR. Imiquimod and resiquimod as novel immunomodulators. J Antimicrob Chemother 2002; 48:751-755. This reviews current and future uses of imiquimod and resiquimod.
5. Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27:571-577. This is an excellent review of imiquimod's mechanisms of action and clinical uses.
6. Tyring S. Immune-response modifiers: A new paradigm in the treatment of human papillomavirus. Curr Ther Res Clin Exp 2000; 61:584-596.
7. Tyring SK, Conant M, Marini M, et al. Imiquimod: an international update on therapeutic uses in dermatology. Int J Dermatol 2002; 41:810-816. The authors provide a good review of clinical application in dermatology.
8. Koutsky LA, Galloway DA, Holmes KK. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 1988; 10:122-163.
9. Garland SM. Human papillomavirus update with a particular focus on cervical disease. Pathology Broadsheet 2002; 34:213-224.
10. IARC International Agency for Research on Cancer. Monographs on the evaluation of the carcinogenic risks to humans. Human papillomaviruses Lyon. IARC Monogr Eval Carcinog Risks Hum 1995; 64:196-212.
11. Coleman N, Birley HD, Renton AM, et al. Immunological events in regressing genital wart. Am J Clin Pathol 1994; 102:768-774.
12. Tyring ST, Arany I, Stanley MA, et al. A randomised, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. J Infect Dis 1998; 178:551-555.
13. Centers for Disease Control and Prevention. 2002 Sexually transmitted diseases treatment guidelines. MMWR Recomm Rep 2002; 51 (RR-6):1-78.
14. Tatti S, Belardi G, Marini M, et al. Consenso en la metodologia de diagnóstica y terapeutica para las verrugas anogenitales [in Spanish]. Revista Obstetricia y Ginecologia Latino-americanas 2001; 59(3). 1
15. von Krogh G, Lacey CJN, Gross G, et al. European course on HPV-associated pathology: Guidelines for the diagnosis and management of anogenital warts. Sex Tran Inf 2000; 76:162-168.
16. Antibiotic Writing Group. Genital (reproductive) tract infections. Therapeutic guidelines: antibiotic. Version 12. Melbourne: Therapeutic Guidelines Limited; 2003.
17. Beutner KR, Tyring SK, Trofatter KF, et al. Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother 1998; 42:789-794.
18. Edwards L, Ferenczy A, Eron L, et al. Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human Papilloma Virus. Arch Dermatol 1998; 134:25-30.
19. Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier. J Am Acad Dermatol 1998; 38:230-239.
20. Garland SM, Sellors JW, Wikstrom A, et al. and the Imiquimod Study Group. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts: results of an open-label, multicentre Phase IIIB trial. Int J STD AIDS 2001; 12:722-729. This describes a large multicentre study (943 patients) of safety and efficacy of imiquimod for external genital warts.
21. Gollnick H, Barasso R, Jappe U, et al. Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. Int J STD AIDS 2001; 12:22-28. The authors describe successful penile lesion clearance (62%) in uncircumcised males with three times per week regimen.
22. Buck HW, Fortier M, Knudsen J, Paavonen J. Imiquimod 5% cream in the treatment of anogenital warts in female patients. 2002 Int J Gyn Obs 2002; 77:231-238. This was an analysis of female participants of two open label studies with 6-month treatment free follow-up period and 75% cleared warts.
23. Hoyme UB, Hagedorn M, Schindler AE, et al. Effect of adjuvant imiquimod 5% cream on sustained clearance of anogenital warts following laser treatment. Infect Dis Obstet Gynecol 2002; 10:79-88. In this open-label phase III-B prospective trial of imiquimod after laser therapy with follow up 6 months later imiquimod was safe, well tolerated, had a sustained response, and low rate of recurrences.
24. Carrasco D, vander Straten M, Tyring S. Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions. J Am Acad Dermatol 2002; 47 (4 Suppl):S212-S216. Combined immunomodulation and surgery results in a lower rate of recurrence (2-7 years follow-up 15-20%) than surgery alone (65%).
25. Kaspari M, Gutzmer R, Kaspari T, et al. Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. Br J Dermatol 2002; 147:757-759. A novel application of imiquimod via anal tampon after surgery resulted in no recurrences at 9 months after ablation follow-up.
26. Gilson RJC, Shupack JL, Friedman-Kien AE, et al. A randomised controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. AIDS 1999; 13:2397-2404.
27. Wagman FA, Estape RE, Angiolo R, Penalver MA. Self-administered topical 5% imiquimod cream for external anogenital warts in adolescent girls. Obstet Gynecol 2001; 97 (Suppl):14. This paediatric study reported clearance of warts in 79% of girls with a mean time to clearance of 6.5 weeks.
28. O'Mahony C, Law C, Gollnick HPM, Marini M. New patient-applied therapy for anogenital warts is rated favourably by patients. Int J STD AIDS 2001; 12:565-570. This describes patient acceptability of self applied imiquimod treatment.
29. van Seters M, Fons G, van Beurden M. Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. J Reprod Med 2002; 47:701-705. A prospective, observational treatment (no surgery) pilot of 5% imiquimod of 15 cases of histologically proven multifocal high grade VIN resulted in complete or partial resolution in 87% of women.
30. Petrow W, Gerdsen R, Uerlich M, et al. Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br J Dermatol 2001; 145:1022. This is a single case report of successful treatment.
31. Diakomanolis E, Haidopoulos D, Stefanidis K. Treatment of high-grade vaginal intraepithelial neoplasia with imiquimod cream. N Engl J Med 2002; 347:374. Imiquimod was successfully used in three cases of high grade vaginal intraepithelial neoplasia.
32. Hengge UR, Esser S, Schultewolter T, et al. Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. Br J Dermatol 2000; 143:1026-1031.
33. Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for molluscum contagiosum. J Cutan Med Surg 2000; 4:76-82.
34. Barba AR, Kapoor S, Berman B. An open label safety study of topical imiquimod 5% cream in the treatment of molluscum contagiosum in children. Dermatol Online J 2001; 7:20-23. Clearance was achieved in a pretreated paediatric population.
35. Syed TA, Goswami J, Ahmadpour OA, Ahmad SA. Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. J Dermatol 1998; 25:309-313.
36. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. Curr Opin Infect Dis 2002; 15:101-114. This is a critical review of role of HPV in non-melanotic skin cancers.
37. Stockfleth E, Meyer T, Bennenghoff B, Christophers E. Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. Br J Dermatol 2001; 137:1050-1053. In this study 100% clearance (by histology) was reported in the imiquimod arm.
38. Flowers F. Imiquimod in the treatment of actinic keratoses and other intraepithelial neoplasms. Int J Dermatol 2002; 41 (Suppl 1):12-15. Imiquimod was a successful non-surgical treatment of cutaneous neoplasias (AK, Bowen's disease).
39. Mackenzie-Wood A, Kossard S, de Launey J, et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol 2001; 44:462-470.
40. Smith KJ, Germain M, Skelton H. Squamous cell carcinoma in situ (Bowen's disease) in renal transplant patients treated with 5% imiquimod and 5% 5-fluorouracil therapy. Dermatol Surg 2001; 27:561-564.
41. Beutner KR, Geisse JK, Helman D, et al. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. J Am Acad Dermatol 1999; 41:1002-1007.
42. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma. Comparison of Dosing Regimens. Arch Dermatol 2002; 138:1165-1171. This was a dose ranging study for imiquimod (daily, twice daily, 3-7 days per week for 6 weeks) on nodular BCCs.
43. Salasche S. Imiquimod 5% cream: a new treatment option for basal cell carcinoma. Int J Dertmatol 2002; 41 (Suppl 1):16-20. The author provides a review of successful imiquimod therapy for nodular and superficial BCCs
44. Marks R, Gebauer K, Shumack S, et al. The Australian Multicenter Trial Group. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol 2001; 44:807-813. The majority of superficial BCCs were cleared with 5% imiquimod.
45. Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the tretment of superficial basal cell carcinoma: A double blind, randomized, vehicle-controlled study. J Am Acad Dermatol 2002; 47:390-398.
46. Berman B. Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology. Int J Dertmatol 2002; 41 (Suppl 1):7-11. This provides a review of clinical use of imiquimod for anogenital warts, molluscum contagiosum and other dermatological conditions.
47. Agarwal S, Berth-Jones J. Porokeratosis of Mibelli: successful treatment with 5% imiquimod cream. Br J Dermatol 2002; 146:338-339. This is a single case report only and more investigation is required.
48. Berman B, Kaufman J. Pilot study on the effect of postoperative imiquimod 5% cream on the recurrence rate of excised keloids. J Am Acad Dermatol 2002; 47 (4 Suppl):S209-S211. None of 11 keloids recurred after surgical excision following nightly imiquimod for 8 weeks and after follow-up to 6 months postoperatively.
49. Trofatter KF Jr, Ferenczy A, Fife KH, HPV Study Group. Increased frequency of dosing of Imiquimod 5% cream in the treatment of external genital warts in women. Int J Gyn Obstet 2002; 76:191-193. This phase II dose ranging study (twice daily, once daily or three times weekly) showed no significant difference in clearance by increasing frequency above that recommended.
50. Fife KH, Ferenczy A, Douglas JM, et al. The HPV Study Group. Treatment of external genital warts in men using 5% Imiquimod cream applied three times a week, once daily, twice daily or three times a day. Sex Transm Dis 2001; 28:226-231. Optimal dosing was the three times per week regimen (and as approved).
51. Spruance SL, Tyring SK, Cmith MH, Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 2001; 184:196-200. This phase III pilot trial showed that resiquimod has potential for treatment of recurrent genital herpes.
52. Stephenson J. New therapy promising for genital herpes. JAMA 2001; 285:2182-2183. This is a review of the phase III trial with resiquimod.
53. Miller RL, Tomai MA, Harrison CJ, Bernstein DI. Immunomodulation as a treatment strategy for genital herpes: review of the evidence. Int Immunopharmacol 2002; 2:443-451. This is an informative review of imiquimod and resiquimod for genital herpes infection.